I take this quote from the article: "considerations and challenges include scaling up good manufacturing practice (GMP) production" Then I think of J&J and it

I take this quote from the article: "considerations and challenges include scaling up good manufacturing practice (GMP) production" Then I think of J&J and its 15M ruined doses, and then wonder whether pharma co's should provide better access to rank & file managers into scientific journals, particularly stuff they are known to be building. https://www.dailymail.co.uk/health/article-9486801/Emergent-stop-making-new-COVID-19-vaccine-material-Baltimore-plant.html https://www.dailymail.co.uk/health/article-9486801/Emergent-...